[go: up one dir, main page]

US20020083888A1 - Flow synthesis of quantum dot nanocrystals - Google Patents

Flow synthesis of quantum dot nanocrystals Download PDF

Info

Publication number
US20020083888A1
US20020083888A1 US09/751,670 US75167000A US2002083888A1 US 20020083888 A1 US20020083888 A1 US 20020083888A1 US 75167000 A US75167000 A US 75167000A US 2002083888 A1 US2002083888 A1 US 2002083888A1
Authority
US
United States
Prior art keywords
accordance
nanocrystals
product mixture
temperature
heat transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/751,670
Other languages
English (en)
Inventor
Donald Zehnder
Marcel Bruchez
Joseph Treadway
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Quantum Dot Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Dot Corp filed Critical Quantum Dot Corp
Priority to US09/751,670 priority Critical patent/US20020083888A1/en
Assigned to QUANTUM DOT CORPORATION reassignment QUANTUM DOT CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRUCHEZ, MARCEL P., TREADWAY, JOSEPH A., ZEHNDER, DONALD A.
Priority to PCT/US2001/050853 priority patent/WO2002053810A1/fr
Priority to US10/032,809 priority patent/US6682596B2/en
Publication of US20020083888A1 publication Critical patent/US20020083888A1/en
Priority to US10/726,716 priority patent/US7144458B2/en
Assigned to INVITROGEN CORP. reassignment INVITROGEN CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: QUANTUM DOT CORPORATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/60—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
    • C30B29/605—Products containing multiple oriented crystallites, e.g. columnar crystallites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T117/00—Single-crystal, oriented-crystal, and epitaxy growth processes; non-coating apparatus therefor
    • Y10T117/10—Apparatus

Definitions

  • This invention resides in the field of nanocrystalline materials and processes for their manufacture.
  • Quantum-sized particles i.e., those having diameters within the range of about 0.1 nm to about 50 nm, also known as quantum dots or nanocrystals, are known for the unique properties that they possess as a result of both their small size and their high surface area. Some of these particles have unique magnetic properties that make the particles useful in electronic data systems such as recording media, in ferro fluids, and in magnetic tagging elements. Luminescent nanocrystals are particularly useful as detectable labels such as oligonucleotides tags, tissue imaging stains, protein expression probes, and the like, in applications such as the detection of biological compounds both in vitro and in vivo.
  • Luminescent nanocrystals offer several advantages over conventional fluorophores, particularly for multiplexed and/or high sensitivity labeling. Nanocrystals typically have larger absorption cross sections than comparable organic dyes, higher quantum yields, better chemical and photochemical stability, narrower and more symmetric emission spectra, and a larger Stokes shift. Furthermore, the absorption and emission properties vary with the particle size and can be systematically tailored.
  • a variety of methods have been reported for the preparation of nanocrystals. These methods include inverse micelle preparations, arrested precipitation, aerosol processes, and sol-gel processes.
  • a method commonly used for the preparation of binary nanocrystals is one in which an organometallic and elemental set of nanocrystal precursors is injected into a hot solvent as the solvent is being stirred. Product nucleation can begin immediately, but the injection causes a drop in the solvent temperature, which tends to halt the nucleation process. Nucleation and particle growth can be continued by heating the reaction mixture with further stirring, and the temperature can be dropped to stop the reaction when the desired particle size is obtained.
  • the initial reaction conditions i.e., the manner and conditions under which the reaction is initiated, are particularly important in controlling the quality and uniformity of the product, and far more so than in other types of syntheses.
  • Stirred-pot methods suffer in this regard since there are limits to how rapidly and uniformly the temperature of the reaction mixture can be changed or otherwise controlled.
  • the temperature drop that occurs upon injection of the precursors will vary with the precursor temperature prior to injection, the volume of precursor injected and its rate of injection, the volume of the heated solvent, and the stirring efficiency.
  • the difficulty in cooling rapidly when terminating the reaction often means that a lower reaction temperature must be used as a means of avoiding excess reaction.
  • Further difficulties with stirred-pot methods are that they often involve the injection of large volumes of flammable or pyrophoric materials at very high temperatures, or the rapid evolution of gases, all of which present safety hazards.
  • nanocrystals in accordance with this invention, which resides in processes and apparatus for the production of monodisperse luminescent semiconductor nanocrystals, for the application of a coating to nanocrystal cores, and for both.
  • the manufacture of nanocrystals in accordance with this invention is accomplished by first dissolving or dispersing precursor materials capable of reacting to form nanocrystals in a solvent, for example a coordinating solvent, and introducing the resulting reaction mixture into a reaction tube that is embedded or immersed in a heat transfer medium.
  • the application of a coating to nanocrystal cores in accordance with this invention is accomplished by dispersing the nanocrystal cores in a solvent, for example a coordinating solvent, in which are dissolved the precursor materials for the coating, and introducing this reaction mixture into the reaction tube.
  • a solvent for example a coordinating solvent
  • the heat transfer medium is maintained at the desired reaction temperature, and the reaction mixture is passed continuously through the tube.
  • the internal diameter of the tube is preferably small enough to promote rapid transfer of heat from the tube walls to the center of the fluid stream flowing through the tube and hence rapid heating of the continuously flowing stream to the reaction temperature.
  • the flow rate is varied and adjusted, and the tube length selected, to permit control of the reaction. Flow rate, temperature and pressure are all controllable, and in preferred embodiments the reaction is quenched by cooling the product stream upon its emergence from the reaction tube by any of various conventional cooling techniques.
  • Characteristic properties of the product stream such as optical properties, electrical properties, magnetic properties, electromagnetic properties, and the like are detected and a comparison is made between the detected values and a predetermined or preselected target range that is indicative of the product quality sought to be achieved. Any discrepancy or deviation between the detected values and target range can then be used to adjust the variable reaction conditions, such as the temperature of the heat transfer medium, the flow rate of the reaction mixture through the tube, or both, until the product changes sufficiently that the detected values fall within or otherwise conform to the target range.
  • Reaction apparatus in accordance with this invention includes a thermally conductive reaction tube of sufficiently small internal diameter to accomplish effective heat transfer in the flowing stream, a heat transfer medium in thermal contact with the exterior of the reaction tube, a pump or other fluid-driving component for continuously supplying a reactant or precursor mixture to the reaction tube, a monitoring unit to evaluate, measure, or otherwise detect the properties of the product stream, preferably but not necessarily as the product stream leaves the reaction tube, as an indication of the nature and quality of the nanocrystals formed in the reaction mixture during its passage through the reaction tube, and optionally a control loop to adjust the reaction conditions in the tube to correct for any discrepances between the detected values and the target range.
  • FIG. 1 is a process flow diagram of one embodiment of the present invention.
  • FIG. 2 is a process flow diagram of a second embodiment of the present invention.
  • FIG. 3 is a superimposed plot of emission spectra of nanocrystals formed by the process and apparatus of the present invention under various reaction conditions.
  • semiconductor nanocrystal “quantum dot,” “QdotTM nanocrystal,” or simply “nanocrystal” are used interchangeably herein and refer to an inorganic crystallite between about 1 nm and about 1000 nm in diameter or any integer or fraction therebetween, more typically about 2 nm to about 20 nm (such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nm).
  • a semiconductor nanocrystal is capable of emitting electromagnetic radiation upon excitation (i.e., the semiconductor nanocrystal is luminescent) and includes a “core” of one or more first semiconductor materials, and may be surrounded by a “shell” of a second semiconductor material.
  • a semiconductor nanocrystal core surrounded by a semiconductor shell is referred to as a “core/shell” semiconductor nanocrystal.
  • the surrounding “shell” material typically has a bandgap energy that is larger than the bandgap energy of the core material and can be chosen to have an atomic spacing close to that of the “core” substrate.
  • the core and/or shell can be a semiconductor material including, but not limited to, those of the Groups II-VI (ZnS, ZnSe, ZnTe, CdS, CdSe, CdTe, HgS, HgSe, HgTe, MgS, MgSe, MgTe, CaS, CaSe, CaTe, SrS, SrSe, SrTe, BaS, BaSe, BaTe, and the like) and III-V (GaN, GaP, GaAs, GaSb, InN, InP, InAs, InSb, and the like) and IV (Ge, Si, and the like), and alloys or mixtures thereof.
  • Groups II-VI ZnS, ZnSe, ZnTe, CdS, CdSe, CdTe, HgS, HgSe, HgTe, MgS, MgSe, MgTe, CaS, CaSe, CaT
  • luminescence is meant the process of emitting electromagnetic radiation (light) from an object.
  • Luminescence results from a system that is “relaxing” from an excited state to a lower state with a corresponding release of energy in the form of a photon. These states can be electronic, vibronic, rotational, or any combination of these three.
  • the transition responsible for luminescence can be stimulated through the release of energy stored in the system chemically or added to the system from an external source.
  • the external source of energy can be of a variety of types including chemical, thermal, electrical, magnetic, electromagnetic, physical, or any other type excited by absorbing a photon of light, by being placed in an electric field, or through a chemical oxidation-reduction reaction.
  • the energy of the photons emitted during luminescence can be in a range of low-energy microwave radiation to high-energy x-ray radiation.
  • luminescence refers to photons in the range from UV to IR radiation.
  • “Monodisperse particles” include a population of particles wherein at least about 60% of the particles in the population, more preferably 75% to 90% of the particles in the population, or any integer within this range, fall within a specified particle size range.
  • a population of monodisperse particles deviates less than 10% rms (root-mean-square) in diameter and typically less than 5% rms.
  • a monodisperse population of semiconductor nanocrystals upon exposure to a primary light source, is capable of emitting energy in narrow spectral linewidths, as narrow as 12 nm to 60 nm full width of emissions at half peak height (FWHM), and with a symmetric, nearly Gaussian line shape.
  • the linewidths are dependent on, among other things, the size heterogeneity, i.e., monodispersity, of the semiconductor nanocrystals in each preparation. Certain single semiconductor nanocrystal complexes have been observed to have FWHM as narrow as 12 nm to 15 nm.
  • nanocrystalline particles or nanocrystal cores for encapsulation
  • precursors known in the art may be used.
  • Useful precursors are many and varied, depending on the type of nanocrystals to be prepared and the intended use of the nanocrystals.
  • One of the various classes of nanocrystals are those that emit light, and examples are those bearing the empirical formulae CdX or ZnX in which X is a chalcogen.
  • Preferred chalcogens are S, Se and Te, with Se particularly preferred.
  • Preferred nanocrystals are CdSe, CdS, CdTe, and ZnSe.
  • Reactants capable of forming nanocrystals of these materials are organocadmium and organozinc compounds as the source of the Cd and Zn, respectively, and elemental chalcogen or chalcogen-containing compounds as the source of the chalcogen.
  • Other implementations of the invention are the coating of pre-formed nanocrystal cores.
  • the coating is likewise performed in a continuous-flow manner, by placing the cores in a suspension in which starting material(s) that form the coating are dissolved.
  • Coatings of various compositions known in the art can be applied in this manner.
  • One class of coatings are those serving to passivate the cores to improve optical properties such as quantum yield.
  • this class are those bearing the empirical formula ZnY in which Y is S, Se, or a mixture thereof.
  • the process is often facilitated by performing the reaction in the presence of a coordinating solvent or by addition of a coordinating additive.
  • coordinating solvent and “coordinating additive” as used herein denote a solvent or other chemical additive that enters into molecular coordination with the atoms in the reactants that combine to form the nanocrystalline materials or the reactants that combine to form the coatings on the nanocrystal core surfaces or with the nanocrystals themselves.
  • the coordinating solvent thus enhances the solubility of the reactants while also serving as a means of modulating the reactivity of the precursors or the growing nanoparticles.
  • a wide range of solvents that function in this manner can be used, and a preferred group are alkyl phosphines, alkyl phosphine oxides, pyridines, furans, ethers, amines and alcohols.
  • Coordinating solvents that are particularly preferred for cadmium chalcogenide nanocrystals are tri-n-octylphosphine and tri-n-octylphosphine oxide.
  • a coordinating solvent that is particularly preferred for zinc chalcogenide nanocrystals is hexadecylamine.
  • a mixture of tri-n-octylphosphine and tri-n-octylphosphine oxide offers particular benefits, the former potentially serving as a preferential coordinator for Se and the latter for Cd.
  • the reactions performed in accordance with this invention are performed on a continuous-flow basis in the thermally conductive reaction tube.
  • the tube is thermally conductive in order to permit efficient heat transfer between the heat transfer medium surrounding the tube and the reaction mixture flowing through the tube.
  • the efficiency of the heat transfer is also dependent on the internal diameter and wall thickness of the tube and the composition of the heat transfer medium surrounding the tube. While this invention is not intended to be limited to specific values for the diameter and length of the tube, the optimal values of these dimensions will be determined by considerations of the viscosity of the reaction mixture and the pressure drop needed to drive the reaction mixture through the tube, both of which will depend on the concentration of the reactants in the reaction mixture as well as the temperature.
  • reaction tube having an internal diameter of about 1.0 mm or less, and preferably within the range of about 0.1 mm to about 1.0 mm, and most preferably within the range of from about 0.25 mm to about 0.8 mm.
  • the reaction tube will have a wall thickness be great enough to provide dimensional stability and sturdiness to the tube but the wall will otherwise be as thin as possible. If the tube material itself has a high heat conductivity, then the tube will contribute to the heat transfer and the choice of wall thickness will be of little importance. In some cases, as described below, the reaction tube may be continuous with the surrounding heat transfer medium, with essentially no wall thickness.
  • the temperature changes imposed on the reaction mixture during its passage through the reaction tube will likewise depend on the tube diameter, as well as the flow rate of the reaction mixture. Flow rates may vary, and the invention is not intended to be limited to specific flow rates. Nevertheless, effective results will be achieved at flow rates within the range of from about 10 ⁇ L per minute to about 1000 ⁇ L per minute, preferably from about 30 ⁇ L per minute to about 300 ⁇ L per minute.
  • the degree or extent of reaction also depends on the concentrations of the reactants, the length of the reaction tube, and the temperature and pressure at which the reaction tube is maintained. None of these operating parameters are limited to specific values in this invention, and each may vary considerably in accordance with the type of product being prepared and the characteristics and qualities that are sought in the product. The appropriate selection of these parameters is a matter of routine skill to those experienced or familiar with batchwise processes for these reactions. In most applications, it is contemplated that the reaction tube will be from about 3 cm to about 300 cm in length, preferably from about 10 cm to about 100 cm in length. Likewise, the most typical temperatures will be at least about 100° C., and preferably within the range of from about 100° C. to about 400° C., more preferably within the range of about 250° C. to about 400° C. These temperature ranges are applicable to both the nanocrystal core-forming reaction and the coating reaction.
  • the reaction tube itself may be of any configuration that will permit continuous flow and that can be immersed, embedded or otherwise placed in full thermal contact with a heat transfer medium.
  • the tube can be straight, serpentine, coiled, or otherwise shaped.
  • the tube can be made of a variety of materials based upon requirements such as thermal conductivity, flexibility, or chemical reactivity.
  • the tube can also be of composite construction, such as glass-coated stainless steel, to obtain particular combinations of properties.
  • the heat transfer medium can be gas, liquid, or solid. With gas or liquid media, circulation can improve the heat transfer efficiency by creating a more uniform temperature.
  • a solid heat transfer medium can be formed by casting or molding a heat conductive material around the reaction tube.
  • the reaction tube can be formed by forming a bore through a solid block of heat transfer medium, the bore itself serving as the tube.
  • a particularly effective arrangement is the use of a reaction tube with a block of heat conductive metal cast around the tube. Materials of construction are selected as those that are chemically inert to the reaction materials while providing effective heat transfer.
  • Monitoring of the product stream is performed by conventional apparatus for the on-line detection of the determinative or characteristic properties of the product stream.
  • these properties are absorbance of electromagnetic radiation, emission of electromagnetic radiation, both absorbance and emission of electromagnetic radiation, static or dynamic light scattering, refractive index, conductance, and magnetic susceptibility.
  • Static light scattering, dynamic light scattering, or refractive index can be used to assess the size distribution of the particles.
  • Conductance can be used with charged particles to obtain a particle count
  • magnetic susceptibility can be used with magnetic or paramagnetic particles to determine the size distribution, particle count, or both. All of these properties can be detected by techniques that are known in the art using instrumentation that is commercially available.
  • the properties detected are optical properties such as, for example, emission intensity, emission wavelength, full width at half maximum peak height, absorption, light scattering, fluorescence lifetime, or combinations of these properties.
  • Detection can be performed at a site downstream of the reaction tube and heat transfer medium. Alternatively, detection can be performed on-line within the reaction tube itself, in which case a tube that permits such detection is used.
  • suitable tubes are those that are optically transparent.
  • the product mixture is cooled at or near the site where detection is performed. Thus, when on-line detection is performed, the product mixture is preferably cooled as it emerges from the heat transfer medium but before it reaches the on-line detection point.
  • Cooling in these embodiments is done to lower the temperature of the product stream enough to substantially quench any reaction still occurring in the moving stream and to standardize the detection temperature, thereby eliminating variations in the optical properties due to temperature. Cooling can be accomplished by passing the product stream through a cooling tube embedded or immersed in a cooling medium in a manner analogous to the heat transfer medium used to heat the starting materials to reaction temperature. It is often sufficient to cool the material passively by simply removing the heating element at the end of the reaction zone. Alternatively, cooling can be achieved by diluting the product stream with additional solvent at an appropriately low temperature.
  • the injection of additional solvent provides an additional benefit—i.e., when the solvent in which the reaction takes place is a mixture of species such as tri-n-octylphosphine and tri-n-octylphosphine oxide, one of which has a melting point above room temperature, the addition of a further amount of a lower-melting solvent species for cooling purposes can prevent freezing of the higher-melting species and facilitate handling of the product stream.
  • the solvent in which the reaction takes place is a mixture of species such as tri-n-octylphosphine and tri-n-octylphosphine oxide, one of which has a melting point above room temperature
  • the properties that are monitored may be any detectable properties that serve as an indication of the size of the nanocrystals, the thickness of the coating, the surface characteristics, or in general the degree or quality of reaction having occurred in the reaction tube.
  • Absorbance is readily measured by irradiating the product stream with light and determining the absorption spectra.
  • Light scattering is readily measured by illuminating the product stream and detecting the direction or amount of scattered light, either one being characteristic of the properties of the nanocrystals and their chemical composition.
  • Photoluminescence is readily measured by irradiating the product stream with light of an appropriate wavelength to excite the nanoparticles and detecting the emission spectra resulting from the excitation. Conventional spectrophotometers or other light detecting devices can be used.
  • Comparison of the spectra with a target range is then performed to determine whether adjustments are needed to the reaction conditions to shift the spectra into the target range. If the shift can be achieved by a change in the reaction temperature, the comparison can serve as a means of determining how much and in which direction to modify the temperature of the heat transfer medium and hence the temperature in the reaction tube.
  • the comparison can be performed visually in a trial run or at the start of the process or at any time during the progress of the reaction, and adjustments to the temperature can be made manually by the operator.
  • the comparison can be performed by automated instrumentation, and if desired, on a continuous basis, with a corresponding adjustment in temperature or flow rate until the comparison produces a favorable result.
  • FIG. 1 is a process flow diagram illustrating one example of a rudimentary system embodying the principles of this invention.
  • the first stage is a reagent preparation stage 11 in which nanocrystal precursors (for those embodiments involving the formation of nanocrystal cores) are dissolved in a coordinating solvent, or in which preformed nanocrystal cores (for those embodiments involving the coating of the preformed cores) are suspended in a solution of coating precursors dissolved in a coordinating solvent.
  • the resulting reaction mixture is transferred by a computer-controlled syringe pump 12 to the heated reactor 13 , which consists of a stainless steel tube 14 whose inner diameter is 0.01 inch to 0.03 inch (0.25 mm to 0.76 mm) around which a zinc block 15 has been cast.
  • the zinc block is provided with temperature detection and heating connections that permit temperature control of the block 15 (and hence the tube 14 ) to various temperatures up to about 400° C.
  • the product stream passes through a flow-through monitoring cell 16 which includes an ultraviolet light source to excite the nanocrystals in the product stream and a CCD-based miniature spectrometer to measure the emission spectra from the nanocrystals.
  • the emission spectra can be monitored visually by the operator and adjustments made to the temperature of the heated reactor 13 , the syringe pump 12 , or both, to achieve nanocrystals that emit the desired spectra.
  • the emission spectra detected by the monitor can be transmitted to an automated controller 17 which will process the data, compare it to a target spectrum, and transmit signals to either the heated reactor, the syringe pump, or both, to correct the temperature and/or flow conditions. This can be done on a continuous basis until the detected spectra conform to the target spectra to a degree that is acceptable to the operator.
  • the finished nanocrystals are collected in a product recovery unit 18 when the parameters have been adjusted sufficiently to achieve the desired spectral output.
  • An optional added feature in FIG. 1 is the provision of the introduction of cooled diluent 19 to the product stream emerging from the reactor 13 for purposes of quenching the reaction prior to the product mixture reaching the monitoring cell.
  • the diluent 19 is fed through a metering pump 20 to an on-line mixing chamber 21 where it mixes with the product stream.
  • two or more reagents can be supplied by individual pumping units, each under separate control from a centralized controller.
  • the controller signals to the pumping units can be modulated by comparisons of the spectral output of the product stream, thereby adjusting the relative feed rates of the reagents to achieve a product having the desired spectral characteristics.
  • monitoring cells can be placed at two or more locations along the process flow path to monitor the progress of the reaction. This will allow different reagents to be added at different stages of the process, and is particularly useful when the process is used both to form the nanocrystal core and to coat the core.
  • the outputs of all monitoring cells will be received and processed either by individual controllers or by a common controller, and resulting signals emitted by the controller(s) can be used to drive adjustments in the temperatures or pump rates at various points along the process path.
  • separately controlled heating units can be used so that each stage can be individually controlled to its own optimum temperature.
  • individual cooling sites can be incorporated immediately upstream of the entry to each cell.
  • FIG. 2 is a process flow diagram for a process that includes first preparing the nanocrystal core and then applying a coating to the core, incorporating several of the additional features of the preceding paragraph.
  • the core is formed in a heated reactor 41 which is similar in construction to that of FIG. 1, supplied by two reagents 42 , 43 , each fed by individual metering pumps 44 , 45 , then preheated 46 , 47 , and combined in a mixing chamber 48 prior to entry into the reactor 41 .
  • the preheating is optional and may be used when the resulting mixture might suffer a drop in temperature due to the addition of one of the components, or when one of the solvents is a solid at room temperature.
  • the two metering pumps 44 , 45 drive the reaction mixture through the reactor 41 , and the emerging dispersion of nanocrystal cores is cooled by the introduction of a cooled diluent 49 , likewise supplied through a metering pump 50 and mixed with the core dispersion in a mixing chamber 51 .
  • the cooled product stream passes through a monitoring cell 52 which detects the optical properties of the nanocrystal cores in the product stream and forwards the data to a controller 53 where the data is compared to a target and corrective output signals are transmitted to the two reagent metering pumps 44 , 45 , and to the heating unit on the heated reactor 41 .
  • the core suspension upon emerging from the monitor 52 , is combined with coating agent(s) to prepare for the coating reaction which, like the nanocrystal-forming reaction, occurs at an elevated temperature.
  • the coating agent(s) 54 are supplied through a metering pump 55 and mixed with the core dispersion in a mixing chamber 56 .
  • the flow diagram presents two options for delivering the core suspension to the mixing chamber—direct delivery and delivery through a processing unit 57 where the core suspension is concentrated or otherwise treated as described above to prepare the cores for coating. In either case, the new reaction mixture enters the second heated reactor 61 , which is similar in construction and principle to the first heated reactor 41 .
  • the product stream emerging from the second heated reactor contains the coated nanocrystals, and is cooled by a diluent 62 fed through a metering pump 63 and mixed with the product stream in a mixing chamber 64 .
  • the cooled coated nanocrystal stream then enters a second monitoring cell 65 which detects the optical properties of the coated cores and forwards the data to a second controller 66 where the data is compared to a target and corrective output signals are transmitted to the coating agent metering pump 53 and the heating unit on the heated reactor 61 .
  • the product stream is then processed in a processing unit 67 where the coated nanocrystals are recovered from the solvent and any unreacted material.
  • This example demonstrates the use of the present invention in preparing nanocrystals of CdSe, and the ability of an on-line fluorescence monitoring cell to differentiate between products prepared at different reaction temperatures, flow rates and the like.
  • a solution was prepared by dissolving 0.179 g of selenium in 16 mL of tri-n-octylphosphine (TOP) and adding 0.115 mL of dimethyl cadmium.
  • TOP tri-n-octylphosphine
  • TOPO tri-n-octylphosphine oxide
  • the flow rate of the reaction mixture through the tubing was 200 ⁇ L/minute, and the zinc block was variously maintained at temperatures of 280° C., 290° C., 300° C., 310° C., 320° C., 330° C., 340° C., 350° C., and 365° C.
  • Luminescence spectra were obtained for the emerging product formed at each of the nine reaction temperatures, and the results are shown in superimposed curves in FIG. 3.
  • the superimposed curves show that each reaction temperature produced a distinct curve, and that adjustment of the reaction temperature can therefore be used to obtain a product of a particular emission spectrum while still maintaining a narrow size distribution of the particles, as indicated by the peak widths.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Metallurgy (AREA)
  • Mathematical Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Luminescent Compositions (AREA)
US09/751,670 2000-12-28 2000-12-28 Flow synthesis of quantum dot nanocrystals Abandoned US20020083888A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09/751,670 US20020083888A1 (en) 2000-12-28 2000-12-28 Flow synthesis of quantum dot nanocrystals
PCT/US2001/050853 WO2002053810A1 (fr) 2000-12-28 2001-12-26 Synthese en continu de points quantiques de nanocristaux
US10/032,809 US6682596B2 (en) 2000-12-28 2001-12-26 Flow synthesis of quantum dot nanocrystals
US10/726,716 US7144458B2 (en) 2000-12-28 2003-12-02 Flow synthesis of quantum dot nanocrystals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/751,670 US20020083888A1 (en) 2000-12-28 2000-12-28 Flow synthesis of quantum dot nanocrystals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/032,809 Continuation-In-Part US6682596B2 (en) 2000-12-28 2001-12-26 Flow synthesis of quantum dot nanocrystals

Publications (1)

Publication Number Publication Date
US20020083888A1 true US20020083888A1 (en) 2002-07-04

Family

ID=25022988

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/751,670 Abandoned US20020083888A1 (en) 2000-12-28 2000-12-28 Flow synthesis of quantum dot nanocrystals
US10/032,809 Expired - Lifetime US6682596B2 (en) 2000-12-28 2001-12-26 Flow synthesis of quantum dot nanocrystals
US10/726,716 Expired - Lifetime US7144458B2 (en) 2000-12-28 2003-12-02 Flow synthesis of quantum dot nanocrystals

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/032,809 Expired - Lifetime US6682596B2 (en) 2000-12-28 2001-12-26 Flow synthesis of quantum dot nanocrystals
US10/726,716 Expired - Lifetime US7144458B2 (en) 2000-12-28 2003-12-02 Flow synthesis of quantum dot nanocrystals

Country Status (2)

Country Link
US (3) US20020083888A1 (fr)
WO (1) WO2002053810A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186216A1 (en) * 2002-03-27 2003-10-02 Hitachi Software Engineering Co., Ltd. Reaction measurement method for reactions using semiconductor nanoparticles, and quality evaluation method for semiconductor nanoparticles using the same
US20050016851A1 (en) * 2003-07-24 2005-01-27 Jensen Klavs F. Microchemical method and apparatus for synthesis and coating of colloidal nanoparticles
US20060009381A1 (en) * 2004-07-07 2006-01-12 I.P. Randywyck B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
US20070125983A1 (en) * 2001-07-20 2007-06-07 Invitrogen Corporation Methods for the preparation of luminescent nanoparticles using two solvents
US20070128350A1 (en) * 2003-09-04 2007-06-07 Hiroyuki Nakamura Method for manufacturing fine composite particles, apparatus for manufacturing fine composite particles, and fine composite particles
US20070141726A1 (en) * 2005-12-19 2007-06-21 Agency For Science, Technology And Research Detection via switchable emission of nanocrystals
US20080112856A1 (en) * 2003-08-26 2008-05-15 Massachusetts Institute Of Technology Method of preparing nanocrystals
WO2011008151A1 (fr) * 2009-07-17 2011-01-20 Stroem Valter Synthèse surveillée en temps réel de nanoparticules magnétiques à très basse coercivité ayant une distribution granulométrique étroite
EP2599898A1 (fr) * 2011-12-01 2013-06-05 Bayer Intellectual Property GmbH Synthèse continue de nanocristaux InP/ZnS à haut rendement quantique
US20140246624A1 (en) * 2013-03-01 2014-09-04 Rarecyte, Inc. Monochromatic dot ensembles
WO2015075564A3 (fr) * 2013-10-04 2015-07-23 King Abdullah University Of Science And Technology Système et procédé de réalisation de boîtes quantiques
CN116547232A (zh) * 2020-12-07 2023-08-04 信越化学工业株式会社 量子点的表面处理方法及表面处理装置

Families Citing this family (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192778B2 (en) * 1999-10-06 2007-03-20 Natan Michael J Surface enhanced spectroscopy-active composite nanoparticles
US8497131B2 (en) * 1999-10-06 2013-07-30 Becton, Dickinson And Company Surface enhanced spectroscopy-active composite nanoparticles comprising Raman-active reporter molecules
WO2002079764A1 (fr) 2001-01-26 2002-10-10 Nanoplex Technologies, Inc. Nanoparticules sandwich a spectrometrie active exaltees de surface
US20020083888A1 (en) * 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US6794265B2 (en) 2001-08-02 2004-09-21 Ultradots, Inc. Methods of forming quantum dots of Group IV semiconductor materials
US7005669B1 (en) 2001-08-02 2006-02-28 Ultradots, Inc. Quantum dots, nanocomposite materials with quantum dots, devices with quantum dots, and related fabrication methods
US6710366B1 (en) 2001-08-02 2004-03-23 Ultradots, Inc. Nanocomposite materials with engineered properties
US6819845B2 (en) 2001-08-02 2004-11-16 Ultradots, Inc. Optical devices with engineered nonlinear nanocomposite materials
US20030066998A1 (en) 2001-08-02 2003-04-10 Lee Howard Wing Hoon Quantum dots of Group IV semiconductor materials
DE60217530T2 (de) 2001-10-02 2007-10-18 Invitrogen Corp., Carlsbad Verfahren zur halbleiternano partikelsynthese
WO2004008550A2 (fr) * 2002-07-15 2004-01-22 Advanced Research And Technology Institute, Inc. Synthese rapide, a basse temperature, de points quantiques
US6808983B2 (en) * 2002-08-27 2004-10-26 Micron Technology, Inc. Silicon nanocrystal capacitor and process for forming same
JP4039325B2 (ja) * 2002-09-12 2008-01-30 松下電器産業株式会社 画像形成装置
WO2004076056A2 (fr) * 2003-02-26 2004-09-10 Lake Shore Cryotronics Inc. Reacteur chimique microfluidique pour la fabrication de nanoparticules produites chimiquement
WO2005002007A2 (fr) * 2003-03-20 2005-01-06 The Research Foundation Of State University Of Newyork Procede de production de noyaux nanocristallins semi-conducteurs, de coque de noyau, de coque tampon de noyau et systemes multicouches dans un solvant de non coordination utilisant la generation d'agents de surface in situ
US8859000B2 (en) * 2003-05-05 2014-10-14 The Research Foundation Of State University Of New York Synthesis of nanoparticles by an emulsion-gas contacting process
US20070275007A1 (en) * 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
WO2005053649A1 (fr) * 2003-11-05 2005-06-16 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Points quantiques biofonctionnalises destines a l'imagerie biologique
US7645397B2 (en) 2004-01-15 2010-01-12 Nanosys, Inc. Nanocrystal doped matrixes
WO2005067524A2 (fr) * 2004-01-15 2005-07-28 Nanosys, Inc. Matrices dopees avec des nanocristaux
US7253452B2 (en) * 2004-03-08 2007-08-07 Massachusetts Institute Of Technology Blue light emitting semiconductor nanocrystal materials
US8137457B2 (en) * 2004-07-23 2012-03-20 University Of Florida Research Foundation, Inc. One-pot synthesis of high-quality metal chalcogenide nanocrystals without precursor injection
US7465352B2 (en) * 2004-07-23 2008-12-16 University Of Florida Research Foundation, Inc. One-pot synthesis of high-quality metal chalcogenide nanocrystals without precursor injection
US7405002B2 (en) * 2004-08-04 2008-07-29 Agency For Science, Technology And Research Coated water-soluble nanoparticles comprising semiconductor core and silica coating
US7534489B2 (en) * 2004-09-24 2009-05-19 Agency For Science, Technology And Research Coated composites of magnetic material and quantum dots
US7316967B2 (en) 2004-09-24 2008-01-08 Massachusetts Institute Of Technology Flow method and reactor for manufacturing noncrystals
US7368086B2 (en) * 2004-10-29 2008-05-06 Invitrogen Corporation Functionalized fluorescent nanocrystals, and methods for their preparation and use
US20060240590A1 (en) * 2004-11-09 2006-10-26 The Research Foundation Of State University Of New York Controlled synthesis of nanowires, nanodiscs, and nanostructured materials using liquid crystalline templates
EP1838430A2 (fr) * 2004-11-09 2007-10-03 Nanolab Systems OY Procedes et dispositifs pour simplifier la production de nanoparticules, et leurs applications
US20060148103A1 (en) * 2004-12-30 2006-07-06 Yin-Peng Chen Highly sensitive biological assays
US8134175B2 (en) 2005-01-11 2012-03-13 Massachusetts Institute Of Technology Nanocrystals including III-V semiconductors
US7608237B2 (en) * 2005-03-28 2009-10-27 The Research Foundation Of State University Of New York Synthesis of nanostructured materials using liquid crystalline templates
WO2006104464A1 (fr) * 2005-03-31 2006-10-05 Agency For Science, Technology And Research Points quantiques de viroles de cœur cdte/gsh
CA2606018A1 (fr) * 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Conjugues de nanoparticules
EP1877101B1 (fr) * 2005-04-28 2016-11-16 Ventana Medical Systems, Inc. Enzymes conjuguées à des anticorps par un lieur peg hétérobifonctionnel
US7763004B2 (en) * 2005-05-18 2010-07-27 The Procter & Gamble Company Disposable absorbent article having layered containment pockets
US20060271010A1 (en) * 2005-05-24 2006-11-30 Lavon Gary D Loincloth diaper
US8187239B2 (en) 2005-05-31 2012-05-29 The Procter & Gamble Company Side notched folded diaper
WO2007059514A2 (fr) * 2005-11-15 2007-05-24 Oxonica, Inc. Procedes a base de sers pour la detection de bioagents
DK2963011T3 (en) * 2005-11-23 2018-08-06 Ventana Med Syst Inc MOLECULAR CONJUGATE
US7737324B2 (en) 2005-11-23 2010-06-15 The Procter & Gamble Company Disposable absorbent article having deployable chassis ears
US8409863B2 (en) 2005-12-14 2013-04-02 Becton, Dickinson And Company Nanoparticulate chemical sensors using SERS
US7723100B2 (en) 2006-01-13 2010-05-25 Becton, Dickinson And Company Polymer coated SERS nanotag
US7226752B1 (en) 2006-01-19 2007-06-05 Avago Technologies General Ip (Singapore) Pte. Ltd. Methods for detecting an analyte in a sample
WO2007090058A2 (fr) * 2006-01-27 2007-08-09 Oxonica, Inc. Immunoessai de flux latéral faisant intervenir des particules encapsulées en tant que modalité de détection
CA2571904A1 (fr) * 2006-02-15 2007-08-15 Fio Corporation Systeme et methode de detection d'agents pathogenes
EP2044402B2 (fr) * 2006-07-24 2016-11-30 Becton Dickinson and Company Dispositif et procédé pour réaliser un dosage avec des particules magnétiques
JP5576120B2 (ja) 2006-11-01 2014-08-20 ベンタナ・メデイカル・システムズ・インコーポレーテツド ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法
WO2008133660A2 (fr) 2006-11-21 2008-11-06 Qd Vision, Inc. Nanocristaux comprenant un élément du groupe iiia et un élément du groupe va, composition, dispositif et autres produits
WO2008063653A1 (fr) 2006-11-21 2008-05-29 Qd Vision, Inc. Nanocristaux semi-conducteurs et compositions et dispositifs les comprenant
WO2008063652A1 (fr) 2006-11-21 2008-05-29 Qd Vision, Inc. Nanocristaux à semi-conducteurs émettant une lumière bleue et compositions et dispositifs contenant ceux-ci
WO2008063657A2 (fr) * 2006-11-21 2008-05-29 Qd Vision, Inc. Dispositifs luminescents et afficheurs à performance améliorée
WO2008063658A2 (fr) 2006-11-21 2008-05-29 Qd Vision, Inc. Nanocristaux à semi-conducteurs et compositions et dispositifs contenant ceux-ci
DE102006055218A1 (de) * 2006-11-21 2008-05-29 Bayer Technology Services Gmbh Kontinuierliches Verfahren zur Synthese von nanoskaligen metallhaltigen Nanopartikel und Nanopartikeldispersion
CA2580589C (fr) 2006-12-19 2016-08-09 Fio Corporation Systeme de detection microfluidique
US20080216894A1 (en) * 2007-01-08 2008-09-11 Plextronics, Inc. Quantum dot photovoltaic device
US7857801B2 (en) 2007-03-23 2010-12-28 The Procter & Gamble Company Diaper having deployable chassis ears and stretch waistband
WO2008119184A1 (fr) 2007-04-02 2008-10-09 Fio Corporation Système et procédé de déconvolution de signaux spectraux de fluorescence multiplexés produits par une technique de codage optique par points quantiques
US7682789B2 (en) * 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
WO2008153744A2 (fr) * 2007-05-23 2008-12-18 Ventana Medical Systems, Inc. Supports polymères pour immunohistochimie et hybridation in situ
WO2009000084A1 (fr) 2007-06-22 2008-12-31 Fio Corporation Systèmes et procédés pour fabriquer un polymère dopé par des points quantiques
WO2009006739A1 (fr) 2007-07-09 2009-01-15 Fio Corporation Systèmes et procédés pour améliorer la détection de fluorescence de molécules cibles dans un échantillon de test
US7989153B2 (en) * 2007-07-11 2011-08-02 Qd Vision, Inc. Method and apparatus for selectively patterning free standing quantum DOT (FSQDT) polymer composites
WO2009020430A2 (fr) * 2007-08-06 2009-02-12 Agency For Science, Technology And Research Procédé de formation d'un nanocristal contenant du cadmium
WO2009046540A1 (fr) 2007-10-12 2009-04-16 Fio Corporation Procédé de focalisation d'écoulement et système de création de volumes concentrés de microbilles, et microbilles formées à la suite de celui-ci
GB2457314A (en) 2008-02-11 2009-08-12 Ct Angewandte Nanotech Can Apparatus and method for the manufacture of nanoparticles
US8334976B2 (en) * 2008-03-18 2012-12-18 The Board Of Trustees Of The University Of Illinois Second-order nonlinear susceptibility of a nanoparticle using coherent confocal microscopy
US9525148B2 (en) 2008-04-03 2016-12-20 Qd Vision, Inc. Device including quantum dots
CN105870345B (zh) 2008-04-03 2019-01-01 三星研究美国股份有限公司 包括量子点的发光器件
HU230862B1 (hu) * 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
WO2009149013A2 (fr) 2008-06-05 2009-12-10 Ventana Medical Systems, Inc. Compositions comprenant des nanomatériaux et procédé d'utilisation de ces compositions pour des processus histochimiques
WO2009153669A2 (fr) * 2008-06-17 2009-12-23 National Research Council Of Canada Points quantiques atomiques
CN102132330B (zh) 2008-06-25 2015-07-22 Fio公司 生物威胁警报系统
DK2334827T3 (da) 2008-08-22 2015-06-15 Ventana Med Syst Inc Metode til kromogen påvisning af to eller flere målmolekyler i en enkelt prøve
RU2515209C2 (ru) 2008-08-29 2014-05-10 Эф-Ай-Оу Корпорейшн Одноразовый портативный диагностический прибор и соответствующая система и способ исследования биологических и природных образцов
WO2010074787A2 (fr) * 2008-10-03 2010-07-01 Life Technologies Corporation Procédé et appareil pour la synthèse de nanocristaux en écoulement continu
KR101147840B1 (ko) 2008-10-27 2012-05-21 한국기계연구원 복수의 가열 영역을 가지는 양자점 제조 장치 및 양자점 제조 방법
KR101078050B1 (ko) * 2008-10-27 2011-10-31 한국기계연구원 양자점 제조 장치 및 양자점 제조 방법
EP2208526A1 (fr) 2008-12-30 2010-07-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Auto-synthétiseur pour la synthèse contrôlée de nano et sous-nanostructures
CN102348986B (zh) 2009-01-13 2015-05-06 Fio公司 与电子设备和快速诊断测试中的测试盒结合使用的手持诊断测试设备和方法
CN104387772B (zh) 2009-05-01 2017-07-11 纳米系统公司 用于纳米结构体分散的官能化基质
JP5540102B2 (ja) 2009-10-12 2014-07-02 ベンタナ メディカル システムズ， インコーポレイテッド 高められた病理学的決定のための複数モダリティコントラストおよび明視野コンテキスト表現、および組織内の複数検体検出
CA2780827A1 (fr) 2009-12-31 2011-07-07 Ventana Medical Systems, Inc. Procedes de production de sondes d'acide nucleique a specificite unique
EP2531569B1 (fr) 2010-02-02 2017-01-25 Ventana Medical Systems, Inc. Composition et procédé de stabilisation de particules fluorescentes
KR101180980B1 (ko) 2010-02-12 2012-09-10 한국기계연구원 다중껍질 양자점의 제조장치 및 제조방법
USPP22463P3 (en) * 2010-02-16 2012-01-17 Menachem Bornstein Gypsophila plant named ‘Pearl Blossom’
EP2539355B1 (fr) 2010-02-26 2016-10-05 Ventana Medical Systems, Inc. Hybridation in-situ avec des sondes polytag
CA2786853A1 (fr) 2010-02-26 2011-09-01 Ventana Medical Systems, Inc. Analyse cytogene de chromosomes en metaphase
CA2800936A1 (fr) 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Conjugues d'haptene pour une detection de cible
EP4524568A3 (fr) 2010-07-23 2025-06-18 Astellas Institute for Regenerative Medicine Procédés de détection de sous-populations rares de cellules et compositions de cellules hautement purifiées
AU2011352251B2 (en) 2010-12-30 2015-05-28 Ventana Medical Systems, Inc. Enhanced deposition of chromogens utilizing pyrimidine analogs
US20130344335A1 (en) 2011-01-21 2013-12-26 Shanghai Institute Of Ceramics, Chinese Academy Of Sciences Application and synthesis of doped vanadium dioxide powder and dispersing agent
US9448231B2 (en) 2011-02-28 2016-09-20 Ventana Medical Systems, Inc. Application of quantum dots for nuclear staining
CA2825453C (fr) 2011-03-14 2016-05-10 Ventana Medical Systems, Inc. Procede d'analyse des translocations chromosomiques et systeme associe
EP2705165B1 (fr) 2011-05-04 2016-08-24 HTG Molecular Diagnostics, Inc. Améliorations apportées à un test quantitatif de protection contre la nucléase (qnpa) et à un séquençage
EP2726628B1 (fr) 2011-07-01 2016-05-11 HTG Molecular Diagnostics, Inc. Procédés de détection de fusions de gènes
GB2494659A (en) * 2011-09-14 2013-03-20 Sharp Kk Nitride nanoparticles with high quantum yield and narrow luminescence spectrum.
WO2013057586A1 (fr) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions et procédés de production de récepteurs solubles des lymphocytes t
WO2013108126A2 (fr) 2012-01-16 2013-07-25 University Of Oslo Méthyltransférases et leurs utilisations
WO2013123390A1 (fr) 2012-02-16 2013-08-22 Qd Vision, Inc. Procédé de préparation de nanocristaux semi-conducteurs
WO2013167387A1 (fr) 2012-05-10 2013-11-14 Ventana Medical Systems, Inc. Sondes spécifiques uniques pour pten, pik3ca, met, top2a et mdm2
US9139770B2 (en) 2012-06-22 2015-09-22 Nanosys, Inc. Silicone ligands for stabilizing quantum dot films
JP5532356B2 (ja) * 2012-06-28 2014-06-25 国立大学法人東京工業大学 表面修飾されたフェライト微粒子の製造方法、表面修飾されたフェライト微粒子の製造装置、フェライト微粒子の製造装置
TWI596188B (zh) 2012-07-02 2017-08-21 奈米系統股份有限公司 高度發光奈米結構及其製造方法
US11242564B2 (en) 2012-07-12 2022-02-08 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
DE102012215421B4 (de) 2012-08-30 2019-08-29 Centrum Für Angewandte Nanotechnologie (Can) Gmbh Verfahren zur Herstellung von Kern/Schale-Nanopartikeln
WO2014048942A1 (fr) 2012-09-25 2014-04-03 Ventana Medical Systems, Inc. Sondes pour pten, pik3ca, met et top2a, et procédés d'utilisation de ces sondes
WO2014139979A1 (fr) 2013-03-12 2014-09-18 Ventana Medical Systems, Inc. Hybridation in situ de points quantiques
KR102203599B1 (ko) 2013-03-14 2021-01-14 나노시스, 인크. 무용매 양자점 교환 방법
DE102013206077A1 (de) * 2013-04-05 2014-10-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Blau-emittierende Leuchtdioden auf Basis von Zinkselenid-Quantenpunkten
CN105283754A (zh) 2013-06-03 2016-01-27 文塔纳医疗系统公司 用于组织检测的荧光成像系统
US9306110B2 (en) 2013-07-31 2016-04-05 US Nano LLC Apparatus and methods for continuous flow synthesis of semiconductor nanowires
WO2015036405A1 (fr) 2013-09-10 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de diagnostic et de traitement d'un carcinome basocellulaire
WO2015069787A1 (fr) 2013-11-05 2015-05-14 Htg Molecular Diagnostics, Inc. Procédés de détection d'acides nucléiques
EP3617322A1 (fr) 2014-02-24 2020-03-04 Ventana Medical Systems, Inc. Détection automatisée d'arn à l'aide de sondes oligonucléotidiques d'arn 2'-o-méthyle marquées et de systèmes d'amplification de signal
ES2688079T3 (es) 2014-06-06 2018-10-30 Ventana Medical Systems, Inc. Significación de la heterogeneidad de HER2 intratumoral en el cáncer de mama y usos de la misma
ES2964769T3 (es) 2014-09-24 2024-04-09 Exscientia Gmbh Monocapa de PBMC o células de médula ósea y usos de la misma
AU2015333761B2 (en) 2014-10-13 2022-04-07 Administrators Of The Tulane Educational Fund Device and method for changing solution conditions in serial flow
EP3009147A1 (fr) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé de traitement de glioblastome résistant
EP3247803A1 (fr) 2015-01-12 2017-11-29 INSERM - Institut National de la Santé et de la Recherche Médicale Méthodes pour le diagnostic du cancer du pancréas
EP3254110B1 (fr) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Analyse histochimique pour évaluer l'expression du ligand de mort programmée 1 (pd-l1)
CN104986726A (zh) * 2015-02-25 2015-10-21 王建伟 一种工业化大批量稳定制备量子点的方法
EP3271725A1 (fr) 2015-03-16 2018-01-24 Ventana Medical Systems, Inc. Matériels et méthodes permettant de détecter des variants d'épissage du récepteur des androgènes et leurs utilisations
WO2016166169A1 (fr) 2015-04-17 2016-10-20 Spring Bioscience Corporation Anticorps, compositions et procédés d'immunohistochimie permettant la détection de c4.4a
WO2016189065A1 (fr) 2015-05-26 2016-12-01 Ventana Medical Systems, Inc. Méthode et système d'évaluation de la qualité de la coloration pour l'immunocytochimie et l'hybridation in situ
WO2017029391A1 (fr) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle méthode de traitement du cancer
CN105038798A (zh) * 2015-08-21 2015-11-11 清华大学 制备硒化镉量子点的方法
WO2017055321A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de fibroblastes dans un prélèvement de tissu
WO2017055324A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules d'origine monocytaire dans un prélèvement de tissu
WO2017055327A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules endothéliales dans un échantillon de tissu
WO2017055320A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé de quantification de la population de lymphocytes cytotoxiques dans un prélèvement de tissu
WO2017055326A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules dendritiques myéloïdes dans un prélèvement de tissu
WO2017055319A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules b dans un prélèvement de tissu
WO2017055322A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de neutrophiles dans un prélèvement de tissu
WO2017055325A1 (fr) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules nk dans un prélèvement de tissu
WO2017060397A1 (fr) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de prédiction du temps de survie de sujets souffrant de métastases d'un mélanome
WO2017067944A1 (fr) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de prédiction du temps de survie de patientes souffrant du cancer du sein triple négatif
EP3371594A1 (fr) 2015-11-06 2018-09-12 Ventana Medical Systems, Inc. Diagnostic représentatif
ES2761266T3 (es) 2015-11-10 2020-05-19 Inst Nat Sante Rech Med Métodos para predicción del tiempo de supervivencia de los pacientes con cirrosis alcohólica descompensada
JP7018021B2 (ja) * 2015-12-31 2022-02-09 ダウ グローバル テクノロジーズ エルエルシー ナノ構造材料の連続フロー合成
US10369538B2 (en) 2015-12-31 2019-08-06 Kuantag Nanoteknolojiler Gelistirme Ve Uretim A.S. Flow system and process for photoluminescent nanoparticle production
US10815424B2 (en) 2015-12-31 2020-10-27 Kuantag Nanoteknolojiler Gelistirme Ve Uretim A.S. One-step process for synthesis of core shell nanocrystals
US10760135B2 (en) 2016-01-13 2020-09-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting pancreatic cancer treatment response
WO2017182834A1 (fr) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle méthode de traitement d'un glioblastome résistant
EP3463452A1 (fr) 2016-05-24 2019-04-10 Institut National de la Sante et de la Recherche Medicale (INSERM) Procédés et compositions pharmaceutiques pour le traitement du cancer du poumon non à petites cellules (cbnpc) qui coexiste avec la bronchopneumopathie chronique obstructive (bpco)
JP2019520071A (ja) 2016-06-14 2019-07-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 急性重症大腸炎の処置応答を予測するための方法
WO2018011107A1 (fr) 2016-07-11 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'er-alpha 46 dans des procédés et des trousses pour évaluer le statut d'un cancer du sein
WO2018011166A2 (fr) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de quantification de la population de cellules dendritiques myéloïdes dans un échantillon de tissu
KR101799479B1 (ko) 2016-07-18 2017-12-20 한국생산기술연구원 양자점 제조 장치 및 이에 의하여 제조되는 비구형 양자점
KR101789986B1 (ko) 2016-07-18 2017-11-20 한국생산기술연구원 다층쉘 구조의 양자점 제조 방법 및 이에 의하여 제조되는 양자점
WO2018046738A1 (fr) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de prédiction du temps de survie de patients souffrant d'un cancer
WO2018046736A1 (fr) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de prédiction du temps de survie de patients souffrant d'un cancer
WO2018054960A1 (fr) 2016-09-21 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de prédiction et de traitement de la résistance à la chimiothérapie dans le lagc à npm-alk(+)
US20200016177A1 (en) 2016-09-22 2020-01-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
WO2018091419A1 (fr) 2016-11-15 2018-05-24 Ventana Medical Systems, Inc. Compositions et procédés de prognostic et de traitement du cancer colorectal
JP2020514701A (ja) 2016-12-19 2020-05-21 ヴェンタナ メディカル システムズ， インク． 定量的免疫組織化学のための方法及びシステム
WO2018122249A1 (fr) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes permettant de prédire le temps de survie de patients souffrant d'un cancer colorectal stable microsatellitaire
WO2018122245A1 (fr) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de prédiction de la durée de survie de patients souffrant d'un cancer colorectal cms3
KR102492563B1 (ko) 2017-02-03 2023-01-27 동우 화인켐 주식회사 양자점의 연속흐름 제조방법 및 양자점 연속흐름 제조장치
WO2018146239A1 (fr) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarqueur de pronostic chez des patients atteints de lam
EP3367098A1 (fr) 2017-02-24 2018-08-29 CeMM - Forschungszentrum für Molekulare Medizin GmbH Procédés permettant de déterminer l'interaction entre des cellules biologiques
WO2018162404A1 (fr) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarqueur pour l'issue chez des patients atteints de lam
WO2018172540A1 (fr) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé de prédiction de la progression de la maladie d'alzheimer
WO2018178171A1 (fr) 2017-03-29 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'évaluation de l'évolution d'une grossesse
WO2018189215A1 (fr) 2017-04-12 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé de prédiction du temps de survie d'un patient souffrant d'un carcinome hépatocellulaire
WO2018192541A1 (fr) * 2017-04-21 2018-10-25 东莞市睿泰涂布科技有限公司 Dispositif de synthèse de précurseur de point quantique et procédé de synthèse de précurseur de point quantique
WO2018192539A1 (fr) * 2017-04-21 2018-10-25 东莞市睿泰涂布科技有限公司 Dispositif de synthèse de cœur de points quantiques et procédé de synthèse de cœur de points quantiques
CN106916584B (zh) * 2017-04-21 2018-06-15 东莞市睿泰涂布科技有限公司 量子点合成装置及量子点合成方法
WO2018192540A1 (fr) * 2017-04-21 2018-10-25 东莞市睿泰涂布科技有限公司 Dispositif de synthèse de points quantiques du type cœur-écorce et procédé de synthèse de points quantiques du type cœur-écorce
WO2019038219A1 (fr) 2017-08-21 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouveau procédé de pronostic du cancer du pancréas
WO2019043138A1 (fr) 2017-09-01 2019-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé de prédiction de l'issue d'un cancer
US11579147B2 (en) 2017-09-25 2023-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of VNN1 as a biomarker and a therapeutic target in sarcomas
CA3079134A1 (fr) 2017-10-31 2019-05-09 Cemm-Forschungszentrum Fur Molekulare Modezin Gmbh Procedes destines a determiner la selectivite de composes d"essai
US11691141B2 (en) 2017-11-13 2023-07-04 Roche Sequencing Solutions, Inc. Devices for sample analysis using epitachophoresis
WO2019207030A1 (fr) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de prédiction d'une réponse à un inhibiteur de point de contrôle immunitaire chez un patient souffrant d'un cancer du poumon
EP3797296B1 (fr) 2018-05-21 2024-09-04 Genentech, Inc. Hétérogénéité de her2 comme biomarqueur dans le cancer
WO2019229489A1 (fr) 2018-05-31 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de mir-146a-5p et de mir-186 en tant que biomarqueurs de l'arthrose
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN112955252B (zh) 2018-10-26 2023-11-21 康涅狄格大学 用于对纳米粒子进行内部和外部修饰的连续处理系统和方法
WO2020089428A1 (fr) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle methode de pronostic du cancer du pancréas
WO2020089432A1 (fr) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle méthode de pronostic du cancer du pancréas
KR20220008253A (ko) 2019-01-03 2022-01-20 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물
JP2022522265A (ja) 2019-01-16 2022-04-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エリスロフェロンの変異体及びその使用
US20220098674A1 (en) 2019-02-13 2022-03-31 Inserm (Institut National De La Santé Et Dr La Recherch Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020182932A1 (fr) 2019-03-13 2020-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelles signatures géniques pour prédire le temps de survie chez des patients souffrant d'un carcinome à cellules rénales
WO2020193740A1 (fr) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle stratégie de traitement du cancer du pancréas
EP3947737A2 (fr) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes
WO2020212586A1 (fr) 2019-04-18 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes pour le traitement du cancer
US20220290237A1 (en) 2019-04-24 2022-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the response of antipsychotic drugs
WO2020229521A1 (fr) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes pour inhiber ou réduire des biolfilms bactériens sur une surface
CN114269916A (zh) 2019-05-14 2022-04-01 豪夫迈·罗氏有限公司 用于样品分析的装置和方法
WO2021001539A1 (fr) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle stratégie pour détecter et traiter une fasciite à éosinophile
US20220340975A1 (en) 2019-09-05 2022-10-27 INSERM (Institute National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
WO2021063968A1 (fr) 2019-09-30 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé et composition pour diagnostiquer une maladie pulmonaire chronique obstructive
CA3157889A1 (fr) 2019-10-17 2021-04-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Procedes de diagnostic d'adenocarcinomes du type intestinal nasal
KR102704730B1 (ko) 2019-10-29 2024-09-10 재단법인대구경북과학기술원 칼코게나이드 화합물 나노입자 대량 합성을 위한 연속식 이중 유동 반응 장치
EP4110823A1 (fr) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Polypeptides ciblant des complexes mage-a3 peptide-mhc et leurs méthodes d'utilisation
WO2021170777A1 (fr) 2020-02-28 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de diagnostic, de pronostic et de gestion du traitement du cancer du sein
EP4121768A1 (fr) 2020-03-20 2023-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode de prédiction de la durée de survie d'un patient atteint d'un cancer
EP4165214A1 (fr) 2020-06-10 2023-04-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthode de traitement et de pronostic du cancer comme le glioblastome
WO2021255204A1 (fr) 2020-06-18 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle stratégie de traitement du cancer du pancréas
WO2022018163A1 (fr) 2020-07-22 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode de prédiction du temps de survie de patients atteints d'un cancer
WO2022064049A1 (fr) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour diagnostiquer une infection à brucella
WO2022084327A1 (fr) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour prédire la réponse à des inhibiteurs du tnf
CN116917502A (zh) 2020-11-06 2023-10-20 Inserm(法国国家健康医学研究院) 诊断和治疗多囊卵巢综合征（pcos）的方法
WO2022136252A1 (fr) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de pronostic de la réponse humorale d'un sujet avant une vaccination
WO2022135753A1 (fr) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de pronostic de la réponse humorale d'un sujet avant la vaccination
WO2022152698A1 (fr) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de npdk-d pour évaluer un pronostic du cancer
KR20220111998A (ko) 2021-02-03 2022-08-10 덕산네오룩스 주식회사 양자점의 제조장치 및 그 제조방법
WO2022171611A1 (fr) 2021-02-09 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé innovant pour le traitement du cancer du poumon
EP4308934A1 (fr) 2021-03-17 2024-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé permettant de diagnostiquer un cancer du pancréas
WO2022207566A1 (fr) 2021-03-29 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouveau procédé pour l'évaluation du pronostic du cancer pancréatique
US20240158861A1 (en) 2021-04-23 2024-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
US20240316005A1 (en) 2021-07-05 2024-09-26 Institut National de la Santé et de la Recherche Médicale Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2023089159A1 (fr) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle stratégie ciblant la diaphonie stroma/cellule tumorale pour traiter un cancer
EP4472740A1 (fr) 2022-01-31 2024-12-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 en tant que biomarqueur et biocible dans des lymphomes t
WO2023152133A1 (fr) 2022-02-08 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé de diagnostic du cancer colorectal
WO2024061930A1 (fr) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale Nouveau procédé de traitement et de diagnostic du lymphome périphérique à cellules t (lcpt)
EP4619510A1 (fr) 2022-11-15 2025-09-24 ETH Zurich Monocouches de cellules séchées à l'air et leurs procédés de préparation
WO2024115935A1 (fr) 2022-11-29 2024-06-06 Inserm Méthodes de traitement d'un lymphome à cellules b à l'aide d'inhibiteurs de cd39
WO2024236131A1 (fr) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Stratifié et procédé pour traiter un patient souffrant d'un cancer
WO2024245951A1 (fr) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combinaison d'un inhibiteur de slc8a1 et d'un antioxydant ciblant les mitochondries pour le traitement du mélanome
WO2025027127A1 (fr) 2023-08-02 2025-02-06 Institut National de la Santé et de la Recherche Médicale Nouvelle méthode de pronostic d'insuffisance rénale
WO2025045894A1 (fr) 2023-08-28 2025-03-06 Institut National de la Santé et de la Recherche Médicale Méthodes et trousses de diagnostic de cause du syndrome néphrotique et d'orientation de la thérapie
WO2025068340A1 (fr) 2023-09-27 2025-04-03 Institut National de la Santé et de la Recherche Médicale Procédé pour prédire l'évolution d'une leucémie myéloïde aiguë (lma)
WO2025073765A1 (fr) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de mélanome
WO2025078632A1 (fr) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de cancer
WO2025109147A1 (fr) 2023-11-24 2025-05-30 Institut National de la Santé et de la Recherche Médicale Méthode de prédiction du risque d'événement cardiovasculaire chez un patient atteint de diabète de type 2
WO2025114473A1 (fr) 2023-11-29 2025-06-05 Institut National de la Santé et de la Recherche Médicale Procédé d'évaluation des maladies associées à une perte de fonction de p53 chez des sujets en ayant besoin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747180A (en) * 1995-05-19 1998-05-05 University Of Notre Dame Du Lac Electrochemical synthesis of quasi-periodic quantum dot and nanostructure arrays
US5850064A (en) 1997-04-11 1998-12-15 Starfire Electronics Development & Marketing, Ltd. Method for photolytic liquid phase synthesis of silicon and germanium nanocrystalline materials
US5990479A (en) * 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6333110B1 (en) * 1998-11-10 2001-12-25 Bio-Pixels Ltd. Functionalized nanocrystals as visual tissue-specific imaging agents, and methods for fluorescence imaging
US6221602B1 (en) 1998-11-10 2001-04-24 Bio-Pixels Ltd. Functionalized nanocrystals and their use in labeling for strand synthesis or sequence determination
US6179912B1 (en) * 1999-12-20 2001-01-30 Biocrystal Ltd. Continuous flow process for production of semiconductor nanocrystals
US6225198B1 (en) 2000-02-04 2001-05-01 The Regents Of The University Of California Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
US20020083888A1 (en) * 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070125983A1 (en) * 2001-07-20 2007-06-07 Invitrogen Corporation Methods for the preparation of luminescent nanoparticles using two solvents
EP2218762A2 (fr) 2001-07-20 2010-08-18 Life Technologies Corporation Nanoparticules luminescentes et leurs procédés de préparation
US20030186216A1 (en) * 2002-03-27 2003-10-02 Hitachi Software Engineering Co., Ltd. Reaction measurement method for reactions using semiconductor nanoparticles, and quality evaluation method for semiconductor nanoparticles using the same
US20050016851A1 (en) * 2003-07-24 2005-01-27 Jensen Klavs F. Microchemical method and apparatus for synthesis and coating of colloidal nanoparticles
US20080087545A1 (en) * 2003-07-24 2008-04-17 Massachusetts Institute Of Technology Microchemical method and apparatus for synthesis and coating of colloidal nanoparticles
US20080112856A1 (en) * 2003-08-26 2008-05-15 Massachusetts Institute Of Technology Method of preparing nanocrystals
US8017235B2 (en) 2003-09-04 2011-09-13 National Institute Of Advanced Industrial Science And Technology Method for manufacturing fine composite particles, apparatus for manufacturing fine composite particles, and fine composite particles
US20070128350A1 (en) * 2003-09-04 2007-06-07 Hiroyuki Nakamura Method for manufacturing fine composite particles, apparatus for manufacturing fine composite particles, and fine composite particles
US20060009381A1 (en) * 2004-07-07 2006-01-12 I.P. Randywyck B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
US20070141726A1 (en) * 2005-12-19 2007-06-21 Agency For Science, Technology And Research Detection via switchable emission of nanocrystals
WO2011008151A1 (fr) * 2009-07-17 2011-01-20 Stroem Valter Synthèse surveillée en temps réel de nanoparticules magnétiques à très basse coercivité ayant une distribution granulométrique étroite
EP2599898A1 (fr) * 2011-12-01 2013-06-05 Bayer Intellectual Property GmbH Synthèse continue de nanocristaux InP/ZnS à haut rendement quantique
WO2013079423A1 (fr) * 2011-12-01 2013-06-06 Bayer Intellectual Property Gmbh Synthèse continue de nanocristaux inp/zns à rendement quantique élevé
US9577149B2 (en) 2011-12-01 2017-02-21 Quantum Materials Corporation Continuous synthesis of high quantum yield InP/ZnS nanocrystals
US20140246624A1 (en) * 2013-03-01 2014-09-04 Rarecyte, Inc. Monochromatic dot ensembles
WO2015075564A3 (fr) * 2013-10-04 2015-07-23 King Abdullah University Of Science And Technology Système et procédé de réalisation de boîtes quantiques
US20160237344A1 (en) * 2013-10-04 2016-08-18 King Abdullah University Of Science And Technology System and method for making quantum dots
US20180312753A1 (en) * 2013-10-04 2018-11-01 King Abdullah University Of Science And Technology System and method for making quantum dots
US10301543B2 (en) * 2013-10-04 2019-05-28 King Abdullah University Of Science And Technology System and method for making quantum dots
US10767110B2 (en) * 2013-10-04 2020-09-08 King Abdullah University Of Science And Technology System and method for making quantum dots
US11518934B2 (en) * 2013-10-04 2022-12-06 King Abdullah University Of Science And Technology System and method for making quantum dots
CN116547232A (zh) * 2020-12-07 2023-08-04 信越化学工业株式会社 量子点的表面处理方法及表面处理装置

Also Published As

Publication number Publication date
US7144458B2 (en) 2006-12-05
WO2002053810A1 (fr) 2002-07-11
US20020144644A1 (en) 2002-10-10
US6682596B2 (en) 2004-01-27
US20040247517A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
US20020083888A1 (en) Flow synthesis of quantum dot nanocrystals
US7229497B2 (en) Method of preparing nanocrystals
US8101021B2 (en) Flow method and reactor for manufacturing nanocrystals
Yen et al. A continuous‐flow microcapillary reactor for the preparation of a size series of CdSe nanocrystals
US6179912B1 (en) Continuous flow process for production of semiconductor nanocrystals
US20110229397A1 (en) Process and apparatus for continuous flow synthesis of nanocrystals
JP5324459B2 (ja) ナノサイズ金属含有ナノ粒子およびナノ粒子分散体の合成方法
JP4269842B2 (ja) 半導体ナノ微結晶の製造方法
WO2005023704A1 (fr) Procede et appareil de production de microparticules composites, et microparticules composites ainsi obtenues
Tian et al. Microfluidic synthesis of monodispersed CdSe quantum dots nanocrystals by using mixed fatty amines as ligands
US9932233B2 (en) Process for making precision nanoparticles by hydrothermal flow manufacturing
US20150014586A1 (en) Method of making quantum dots
JP6099273B2 (ja) マイクロリアクター装置
CA2883045A1 (fr) Procede de preparation de nanoparticules noyau/enveloppe et nanoparticules noyau/enveloppe
US20080044340A1 (en) Method for Producing Highly Monodisperse Quantum Dots
CN114538369A (zh) 纳米结构材料的连续流动合成
Misuk et al. Segmented Flow‐Based Multistep Synthesis of Cadmium Selenide Quantum Dots with Narrow Particle Size Distribution
Wan et al. Continuous synthesis of CdSexTe1− x nanocrystals: Chemical composition gradient and single-step capping
Zhang et al. The synthesis of ZnxCd1-xSe quantum dots with a wide range of emission maxima
KR102492563B1 (ko) 양자점의 연속흐름 제조방법 및 양자점 연속흐름 제조장치
Hatstat Characterization and Post-Processing of Medical-Grade Quantum Dots
Gonzales et al. Synthesis and Characterization of Colloidal ZnTe/ZnS and ZnTe/ZnSe Quantum Dots
CN119823761A (zh) 量子点的合成方法与量子点
Nakamura et al. Nano-Sized Composite Particle Preparation by a Micro-Fluidic System
Nakamura et al. Nanocrystals Synthesis by Microreactors

Legal Events

Date Code Title Description
AS Assignment

Owner name: QUANTUM DOT CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZEHNDER, DONALD A.;BRUCHEZ, MARCEL P.;TREADWAY, JOSEPH A.;REEL/FRAME:011709/0086

Effective date: 20010313

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: INVITROGEN CORP.,CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:QUANTUM DOT CORPORATION;REEL/FRAME:016862/0372

Effective date: 20051104

Owner name: INVITROGEN CORP., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:QUANTUM DOT CORPORATION;REEL/FRAME:016862/0372

Effective date: 20051104